checkAd

     137  0 Kommentare The Subcutaneous Biologic Drugs and Affiliated Technologies Market is Estimated to be Worth Over USD 180 Billion by 2030, Claims Roots Analysis - Seite 3

    • Deborah Bitterfield (Founder and Chief Executive Officer, Lindy Biosciences)
    • Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)
    • Steve Prestrelski (Founder and Chief Scientific Officer, Xeris Pharmaceuticals), Hong Qi (Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Senior Scientist, Formulation, Xeris Pharmaceuticals)
    • David Daily (Co-Founder and Chief Executive Officer, DALI Medical Devices)
    • Michael Reilly (Co-Founder and Chief Executive Officer and Co-Founder, Excelse Bio)
    • Poonam R Velagaleti (Co-Founder, i-novion)
    • Michael Hooven (Chief Executive Officer, Enable Injections)
    • Frederic Ors (Chief Executive Officer, Immunovaccine Technologies)
    • Patrick Anquetil (Chief Executive Officer, Portal Instruments)
    • Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
    • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services)
    • David Heuzé (Communication Leader, MedinCell)

    The research covers detailed profiles of key players (listed below); each profile features overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.

    • Adocia
    • Ajinomoto Bio-Pharma Services
    • Arecor
    • Alteogen
    • Ascendis Pharma
    • Avadel Pharmaceuticals
    • Camurus
    • Creative BioMart
    • Creative Biolabs
    • DURECT
    • Eagle Pharmaceuticals
    • Halozyme Therapeutics
    • MedinCell
    • Xeris Pharmaceuticals
    • Serina Therapeutics

    For additional details, please visit 

    https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html or email sales@rootsanalysis.com 

    You may also be interested in the following titles:

    1. Global Autoinjectors Market (3rd Edition), 2020-2030
    2. Prefilled Syringes Market (5th Edition), 2020-2030
    3. Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030
    4. Large Volume Wearable Injectors Market (4th Edition), 2018-2030

    Contact:
    Gaurav Chaudhary
    +1-(415)-800-3415
    +44-(122)-391-1091
    Gaurav.Chaudhary@rootsanalysis.com

    LOGO: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

    Seite 3 von 3




    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    The Subcutaneous Biologic Drugs and Affiliated Technologies Market is Estimated to be Worth Over USD 180 Billion by 2030, Claims Roots Analysis - Seite 3 LONDON, May 26, 2020 /PRNewswire/ - Roots Analysis has announced the addition of "Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030" report to its list of offerings. Several approved therapeutic products, which …